Assertio Therapeutics Announces Appointment of Jay Galeota to Board of Directors
April 01 2019 - 9:00AM
Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that
James (Jay) J. Galeota, Jr. has been appointed to the Company’s
Board of Directors. Mr. Galeota most recently served as the
President and Chief Operating Officer of G&W Laboratories, Inc.
“We are thrilled to welcome Jay to our Board of Directors,” said
Arthur Higgins, President and CEO of Assertio. “Jay brings decades
of strategic and operational pharmaceutical experience to our
Board.”
“I am excited about the future of Assertio and look forward to
helping the Company advance patient care as a member of the Board,"
said Mr. Galeota.
Mr. Galeota, 52, served as the President and Chief Operating
Officer of G&W Laboratories, Inc. from 2016 to 2019. From
1988 to 2016, Mr. Galeota served in many diverse positions at Merck
& Co., Inc., where he served most recently as Chief Strategy
and Business Development Officer and President, Emerging
Businesses. From 2011 to 2014, he served as President, Hospital and
Specialty Care at Merck, and from 2009 to 2011, he served as Senior
Vice President of Global Human Health Strategy and Business
Development. Mr. Galeota started his career in Merck’s commercial
organization, where he held various U.S. and global leadership
positions and led numerous brands and key product launches across a
variety of therapeutic areas. Mr. Galeota currently serves as a
director of Melinta Therapeutics, Inc., a publicly-held
pharmaceutical company. Mr. Galeota holds a B.S. in biology from
Villanova University and is a graduate of Harvard Business School’s
Advanced Management Program.
About Assertio Therapeutics, Inc.Assertio
Therapeutics is committed to providing responsible solutions to
advance patient care in the Company’s core areas of neurology,
orphan and specialty medicines. Assertio currently markets three
FDA-approved products and continues to identify, license and
develop new products that offer enhanced options for patients that
may be underserved by existing therapies. To learn more about
Assertio, visit www.assertiotx.com.
"Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995This news release contains
forward-looking statements. These statements involve inherent risks
and uncertainties that could cause actual results to differ
materially from those projected or anticipated, including risks
related to regulatory approval and clinical development of
long-acting cosyntropin, expectations regarding royalties to be
received based on sales of NUCYNTA and NUCYNTA ER, expectations
regarding potential business opportunities and other risks outlined
in the Company's public filings with the Securities and Exchange
Commission, including the Company's most recent annual report on
Form 10-K and subsequent Quarterly Reports on Form 10-Q. All
information provided in this news release speaks as of the date
hereof. Except as otherwise required by law, the Company undertakes
no obligation to update or revise its forward-looking
statements.
Investor and Media Contact:John B. Thomas SVP,
Investor Relations and Corporate Communications
jthomas@assertiotx.com
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Apr 2023 to Apr 2024